Processing...
Clinical Trials for Sarcoma
Search
Search
There are 158 active trials for advanced/metastatic sarcoma.
Click on a trial to see more information.
158 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Enrolls adults with relapsed/refractory or treatment-ineligible advanced/metastatic solid tumors (ECOG 0–1) who have at least two injectable lesions, with emphasis on cutaneous and head/neck cancers (e.g., cSCC, BCC, melanoma, Merkel cell carcinoma, HNSCC) including anti–PD-1–refractory cohorts. Patients receive intratumoral MQ710/MQ719, a non-replicating modified vaccinia Ankara virotherapy (E5R-deleted to enhance cGAS/STING signaling and engineered to express Flt3L and OX40L), given in escalating multi-dose schedules alone or combined with systemic pembrolizumab (PD-1 inhibitor).
ClinicalTrials.gov ID: NCT05859074
TrialFetch AI summary: Adults with locally advanced unresectable or metastatic solid tumors harboring a KRAS alteration (mutation or amplification) who have progressed on, are ineligible for, or declined standard-of-care therapy (Arm D additionally requires PD-L1 TPS ≥50%; excludes untreated CNS metastases and ILD/pneumonitis). Participants receive the first-in-human agent BMS-986523 (target/mechanism not publicly described) as monotherapy or combined with pembrolizumab (anti–PD-1), cetuximab (anti-EGFR), or gemcitabine plus nab-paclitaxel.
ClinicalTrials.gov ID: NCT07223047
TrialFetch AI summary: Enrolls children/AYA age >12 months to <30 years with recurrent/refractory non-CNS solid tumors (dose-finding/expansion, including an HRR-altered cohort) and randomizes patients with first-relapse, EWSR1-rearranged Ewing sarcoma to compare efficacy. Treatment is nanoliposomal irinotecan (Onivyde; topoisomerase I–mediated DNA damage) on days 1 and 8 of 21-day cycles combined with either talazoparib (PARP1/2 inhibitor with PARP-trapping) or temozolomide (oral DNA-alkylating agent).
ClinicalTrials.gov ID: NCT04901702
TrialFetch AI summary: Enrolls adults with metastatic or locally advanced unresectable solid tumors (ECOG ≤2; measurable/evaluable by RECIST) with biologic rationale for RBM39 degradation; adolescents ≥16 may enroll for Ewing sarcoma or other supported malignancies, and stable treated brain metastases are allowed. Patients receive oral ST-01156, a small-molecule molecular glue RBM39 degrader (RNA-binding/splicing factor), dosed once daily on a 5-days-on/2-days-off schedule in 28-day cycles with dose escalation to define MTD/RP2D and assess early antitumor activity.
ClinicalTrials.gov ID: NCT07197554
TrialFetch AI summary: For adults (≥18) with relapsed/refractory, measurable soft tissue sarcoma after ≥1 prior systemic regimen (ECOG 0–1) whose tumors are FAP-PET–positive, this study treats with IV [Ac-225]RTX-2358, a fibroblast activation protein (FAP)–targeted actinium-225 alpha-emitting radiopharmaceutical delivering high–linear energy transfer cytotoxic radiation to the tumor microenvironment, dosed every 8 weeks for 4 cycles (up to 6 if benefiting). Patients also receive the investigational FAP-targeted PET imaging agent [Cu-64]LNTH-1363S for selection/imaging and dosimetry assessments.
ClinicalTrials.gov ID: NCT07156565
TrialFetch AI summary: Eligible patients are children, adolescents, and young adults (age 1 to <24 years; >10 kg) with relapsed/refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor with measurable/evaluable disease after standard therapies and no known CNS involvement. After fludarabine/cyclophosphamide lymphodepletion, participants receive a single infusion of an autologous 1:1 cellular product combining B7-H3–targeted CAR T cells with PRAME antigen–specific T cells engineered with a dominant-negative TGF-β receptor II (dTβRII) to resist TGF-β–mediated immunosuppression.
ClinicalTrials.gov ID: NCT07172958
TrialFetch AI summary: Adults with ECOG 0–1 and locally advanced unresectable or metastatic sarcoma (≤2 prior metastatic systemic lines) or selected epithelial solid tumors (≤3 prior lines) with RECIST-measurable disease and required pretreatment biopsy/archival tissue are treated with ZL-6201 monotherapy in 21-day cycles. ZL-6201 is a first-in-human LRRC15-targeting antibody–drug conjugate delivering an internalized camptothecin-derivative (topoisomerase I inhibitor) payload via a protease-cleavable linker.
ClinicalTrials.gov ID: NCT07374848
TrialFetch AI summary: For children and adults (age 1–75) with histologically confirmed osteosarcoma that is recurrent, refractory, or progressive with new/worsening measurable or evaluable disease (including FDG-PET–avid bone metastasis not in complete remission after upfront therapy), ECOG 0–2 (or Lansky/Karnofsky ≥60), adequate organ function, and able to undergo leukapheresis (prior anthracycline-based therapy generally required). Patients receive lymphodepleting fludarabine/cyclophosphamide followed by a single infusion of autologous FH-FOLR1 ST CAR T cells targeting folate receptor alpha (FOLR1/FRα) to activate T-cell cytotoxicity against FOLR1-expressing tumor cells.
ClinicalTrials.gov ID: NCT07227571
TrialFetch AI summary: For adolescents and adults (≥30 kg; ECOG 0–2/Lansky ≥50) with histologically confirmed relapsed/refractory osteosarcoma after ≥1 prior chemotherapy regimen and RECIST-measurable/evaluable disease (including FDG-PET–avid bone-only disease). Participants receive single-agent LNTH-2403, an LRRC15-targeted lutetium-177–labeled monoclonal antibody radiotherapeutic delivering beta radiation to LRRC15-expressing tumor/stroma, dosed about every 8 weeks with imaging-based biodistribution/dosimetry.
ClinicalTrials.gov ID: NCT07357519
TrialFetch AI summary: This trial involves adult patients with refractory solid tumors unresponsive or declining standard treatments, evaluating the PCNA inhibitor AOH1996, which targets a cancer-specific variant to impair DNA replication and repair, dosed orally twice daily in a 28-day cycle.
ClinicalTrials.gov ID: NCT05227326